Tivozanib in the treatment of renal cell carcinoma

Mehmet Hepgur, Sarmad Sadeghi, Tanya B Dorff, David I Quinn Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA Abstract: Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urological...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hepgur M, Sadeghi S, Dorff TB, Quinn DI
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/242d5852ebca479689281f0fe367f822
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:242d5852ebca479689281f0fe367f822
record_format	dspace
spelling	oai:doaj.org-article:242d5852ebca479689281f0fe367f8222021-12-02T06:54:18ZTivozanib in the treatment of renal cell carcinoma1177-54751177-5491https://doaj.org/article/242d5852ebca479689281f0fe367f8222013-06-01T00:00:00Zhttp://www.dovepress.com/tivozanib-in-the-treatment-of-renal-cell-carcinoma-a13316https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Mehmet Hepgur, Sarmad Sadeghi, Tanya B Dorff, David I Quinn Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA Abstract: Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urological malignancies and has been associated with poor responses to conventional cytotoxic chemotherapy. Interferon-a and interleukin-2 were previously utilized in a limited number of patients with good performance status due to toxicity and safety issues. Over the last decade, through advances in the understanding of the biology and pathology of RCC, the important role of vascular endothelial growth factor (VEGF) in RCC has been identified. Data from randomized trials have led to the approval of first-generation tyrosine kinase inhibitors (TKIs) sorafenib, sunitinib, and pazopanib; however, these agents inhibit a wide variety of kinase targets and are associated with a range of adverse effects. More recently, a new generation TKI, axitinib, has been approved by the US Food and Drug Administration. Tivozanib is a novel TKI, which is a potent inhibitor of VEGF-1, VEGF-2, VEGF-3, c-kit, and PDGR kinases, with a more restricted target spectrum. Phase II and III studies have demonstrated significant activity and a favorable safety profile as an initial targeted treatment for advanced RCC. This review examines the emerging data with tivozanib for the treatment of advanced RCC. Preclinical investigations as well as Phase I, II, and III data are examined; data on the comparative benefits of tivozanib are reviewed. Finally, we discuss the future potential of tivozanib in combination, biomarkers associated with tivozanib response, and acquisition of resistance and nonkidney cancer indications. Keywords: targeted therapy, renal cell cancer, tyrosine kinase inhibitor, tivozanibHepgur MSadeghi SDorff TBQuinn DIDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 139-148 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Hepgur M Sadeghi S Dorff TB Quinn DI Tivozanib in the treatment of renal cell carcinoma
description	Mehmet Hepgur, Sarmad Sadeghi, Tanya B Dorff, David I Quinn Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA Abstract: Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urological malignancies and has been associated with poor responses to conventional cytotoxic chemotherapy. Interferon-a and interleukin-2 were previously utilized in a limited number of patients with good performance status due to toxicity and safety issues. Over the last decade, through advances in the understanding of the biology and pathology of RCC, the important role of vascular endothelial growth factor (VEGF) in RCC has been identified. Data from randomized trials have led to the approval of first-generation tyrosine kinase inhibitors (TKIs) sorafenib, sunitinib, and pazopanib; however, these agents inhibit a wide variety of kinase targets and are associated with a range of adverse effects. More recently, a new generation TKI, axitinib, has been approved by the US Food and Drug Administration. Tivozanib is a novel TKI, which is a potent inhibitor of VEGF-1, VEGF-2, VEGF-3, c-kit, and PDGR kinases, with a more restricted target spectrum. Phase II and III studies have demonstrated significant activity and a favorable safety profile as an initial targeted treatment for advanced RCC. This review examines the emerging data with tivozanib for the treatment of advanced RCC. Preclinical investigations as well as Phase I, II, and III data are examined; data on the comparative benefits of tivozanib are reviewed. Finally, we discuss the future potential of tivozanib in combination, biomarkers associated with tivozanib response, and acquisition of resistance and nonkidney cancer indications. Keywords: targeted therapy, renal cell cancer, tyrosine kinase inhibitor, tivozanib
format	article
author	Hepgur M Sadeghi S Dorff TB Quinn DI
author_facet	Hepgur M Sadeghi S Dorff TB Quinn DI
author_sort	Hepgur M
title	Tivozanib in the treatment of renal cell carcinoma
title_short	Tivozanib in the treatment of renal cell carcinoma
title_full	Tivozanib in the treatment of renal cell carcinoma
title_fullStr	Tivozanib in the treatment of renal cell carcinoma
title_full_unstemmed	Tivozanib in the treatment of renal cell carcinoma
title_sort	tivozanib in the treatment of renal cell carcinoma
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/242d5852ebca479689281f0fe367f822
work_keys_str_mv	AT hepgurm tivozanibinthetreatmentofrenalcellcarcinoma AT sadeghis tivozanibinthetreatmentofrenalcellcarcinoma AT dorfftb tivozanibinthetreatmentofrenalcellcarcinoma AT quinndi tivozanibinthetreatmentofrenalcellcarcinoma
_version_	1718399677387243520

Tivozanib in the treatment of renal cell carcinoma

Ejemplares similares